Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks.

[1]  J. Bernstein,et al.  Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[2]  J. Bernstein,et al.  Sustained Response Following Acute Treatment Of Hereditary Angioedema Attacks With Recombinant Human C1 Esterase Inhibitor , 2014 .

[3]  P. Williams,et al.  A UK national audit of hereditary and acquired angioedema , 2014, Clinical and experimental immunology.

[4]  K. Beusterien,et al.  The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe. , 2014, Allergy and asthma proceedings.

[5]  C. Hack,et al.  Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema. , 2013, British journal of clinical pharmacology.

[6]  T. Craig,et al.  Review of Recent Guidelines and Consensus Statements on Hereditary Angioedema Therapy with Focus on Self-Administration , 2013, International Archives of Allergy and Immunology.

[7]  R. Lockey,et al.  Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[8]  K. Bork,et al.  Overview of hereditary angioedema caused by C1-inhibitor deficiency: assessment and clinical management. , 2013, European annals of allergy and clinical immunology.

[9]  A. Deykin,et al.  Use of Transgenic Animals in Biotechnology: Prospects and Problems , 2013, Acta naturae.

[10]  J. Bernstein.  HAE update: epidemiology and burden of disease. , 2013, Allergy and asthma proceedings.

[11]  M. Mannesse,et al.  Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits. , 2012, Journal of biotechnology.

[12]  M. Mannesse,et al.  Immunogenicity Assessment of Recombinant Human C1-Inhibitor , 2012, BioDrugs.

[13]  R. Lockey,et al.  WAO Guideline for the Management of Hereditary Angioedema , 2012, The World Allergy Organization journal.

[14]  M. Bottorff,et al.  Thrombotic Events Associated with C1 Esterase Inhibitor Products in Patients with Hereditary Angioedema: Investigation from the United States Food and Drug Administration Adverse Event Reporting System Database , 2012, Pharmacotherapy.

[15]  M. Mannesse,et al.  Immunogenicity assessment of recombinant human c1-inhibitor: an integrated analysis of clinical studies. , 2012, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[16]  J. Speight,et al.  Content Validity of Visual Analog Scales to Assess Symptom Severity of Acute Angioedema Attacks in Adults with Hereditary Angioedema , 2012, The Patient - Patient-Centered Outcomes Research.

[17]  T. Caballero.  Efficacy Assessments in Randomized Controlled Studies of Acute Therapy for Hereditary Angioedema , 2012, Journal of Clinical Immunology.

[18]  M. Triggiani,et al.  Efficacy and safety of recombinant human C1‐inhibitor for the treatment of attacks of hereditary angioedema: European open‐label extension study , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[19]  J. Nuijens,et al.  Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. , 2010, The Journal of allergy and clinical immunology.

[20]  W. Lumry,et al.  The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. , 2010, Allergy and asthma proceedings.

[21]  M. Frank.  Recombinant and Plasma-Purified Human C1 Inhibitor for the Treatment of Hereditary Angioedema , 2010, The World Allergy Organization journal.

[22]  K. Bork,et al.  Hereditary angioedema: new findings concerning symptoms, affected organs, and course. , 2006, The American journal of medicine.

[23]  A. Eerenberg,et al.  A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. , 2005, The Journal of allergy and clinical immunology.